BioLabs’ Post

Pharma Industry Investment Snapshot: 2019-2023 PharmaCircle’s database shows that venture capital investments peaked post-COVID 2021 and subsequently fell 40% in 2023. Other types of investments and product deals are further explored in The Weekly Brief https://lnkd.in/eCbZrP9. #VentureCapital #Investments #Data #PharmaCircle

Many companies find that navigating the complexities of fundraising can be daunting, but you don't have to do it alone. 📈 2024 Highlights: The number of biotech assets in phase 3 clinical trials has increased compared to 2023. 📊 Trend Over a Decade: Over the past ten years, the number of active biotech products in phase 3 trials has increased fourfold. 🏢 Current Landscape: More than 430 companies are currently funding these trials, reflecting an annual growth rate of 13.7% since 2012 🌟 This growth in late-stage trials is attracting more investment into the biotech sector. Investors are typically more confident in funding companies with advanced clinical assets, leading to potentially higher funding rounds and partnerships Whether you're an investor on the hunt for the next big opportunity or a company in need of funding, this group is here to link you with the right people: https://lnkd.in/ey4v9x3U

🚀 Thriving Against the Odds! European-focused VC firms, Forbion and BioGeneration Ventures, break records in biopharma fund raises despite a slower 2023 market. Investors, from Eli Lilly to pension funds, express confidence in the societal impact of life sciences. 💰 Robust Funding Rounds Amid IPO Chill Large funding rounds keep European biotechs well-funded despite a cool IPO scene. 🔬 Sector Resilience and Top-Tier Investments Top-tier companies continue to attract significant capital, showcasing the sector's resilience. Novo Holdings backs the strength of the sector, highlighting significant funds still in play. 🌍 Value Proposition: European Biopharmas European biopharmas remain a compelling value proposition—40-50% cheaper than their U.S. counterparts. #BiotechInvesting #EuropeanBiotech #VCfunding #InnovationThrives Link to the article on the comment section below:

🌐 Insights from Jefferies London Healthcare Conference! 🏥 Antoine Papiernik, Chairman of Sofinnova Partners, shares thoughts on the biotech landscape and funding trends. 💡 🌍 Despite a challenging year, optimism is in the air among attendees. Papiernik notes the positivity and highlights the 740 million euro fund by Gilde Healthcare as evidence that "there's money around." 💰 📉 Funding Challenges: Acknowledging the difficulty in securing funds, Papiernik emphasizes the importance of catching available opportunities, indicating a more positive sentiment than expected. 🚀 🔍 IPO Landscape: Papiernik remains cautious about a significant shift in the IPO landscape, suggesting that acquisitions might be the primary exit route for biotechs. 🔄 🤝 Pharma Appetite: The silver lining lies in the strong appetite among Big Pharmas for biotech acquisitions, demonstrated by recent moves like Eli Lilly and Company acquiring Sofinnova's portfolio company, Mablink Bioscience. 🌐 💼 Future Predictions: Papiernik anticipates potential changes in M&A activity, leading to more transactions and addressing pent-up demand in the biotech sector. 📈 👏 Kudos to the organisers of Jefferies London Healthcare Conference for fostering collaboration and discussions in the European biotech landscape! 🇪🇺💊 #Biotech #HealthcareConference #FundingTrends #IPO #BiotechInvestment #MandA #SofinnovaPartners #JefferiesConference #InnovationInHealthcare 🚑🔬

📊🔬 Chart of the Week: Mega life sciences VC deals remain resilient as investors bet on stability 📈 Larger life sciences VC deals ($150M+) show resilience amid capital market challenges. While smaller deals dropped 68.7%, mega deals increased by 4.0% from 2020 to today.   💰 Investors favor larger deals with late-stage startups in uncertain economic environments. Mega deals involve established companies with robust business models and revenue streams, perceived as having lower risk profiles.   🌟 Notable examples include Kriya Therapeutics ($430M), MapLight Therapeutics ($225M), and Aiolos Bio ($245M).   🔑 Takeaway: The life science sector's mega deals showcase resilience and investor confidence, driven by established companies with strong business models and revenue streams, even during challenging market conditions.   #JLL #ChartOfTheWeek #LifeSciences #MegaDeals #VentureCapital #Investment #Resilience #Stability #SanDiego #JLLTech #MarketTrends #Innovation 

Life Science Chart of the Week: Highest ever level of public market capital into the biotech industry is promising for market demand   ● Public investment into the biopharma industry grew tremendously in Q1 2024, surpassing previous highs seen in 2020 and 2021. IPO investment was up 254% year-over-year with 13 companies going public in Q1, versus 28 companies in all of 2023. ● Similarly, there was influx of $8.7 billion to 90 companies via secondary offerings in the first quarter of the year, nearly 5x the capital investment seen in Q1 2023. Of the group, only four companies are profitable today indicating most of these organizations are without revenue-generating drugs and in need of this round of funding. ● This uptick comes at a time when private growth capital, namely venture capital, has slowed across the industry. Q1 venture capital flows were 35% lower than the quarterly average of 2021 and 2022. Additionally, the NASDAQ Biotechnology Index is up 8.7% over the past six months indicating strength in the stock market as well as in the industry. ● Biopharma companies that go public or raise additional capital through secondary offerings typically use funds for operations with the potential to expand. This increase in public market activity will provide additional capital for organizations to tap into. Hopefully, this will limit space givebacks and lead to possible space expansions. #JLL #JLLResearch #Innovation #SanDiego #LifeScience #IPO

An increase in down rounds in 2023 indicates a reassessment of valuations in VC. Challenges are expected to persist in the sector through the H1 of 2024, grappling with repercussions from previous excesses and a challenging fundraising environment. The initiation of a new year in healthcare and life sciences business development and finance coincides with the annual J.P. Morgan Healthcare Conference, sparking renewed optimism for ventures. Read our full review of venture activity in biopharma and broader healthcare. https://hubs.ly/Q02kpN-t0

Maximizing Biotech Prospects via Knowledge and Practice At the foundation of Evergrowth BioHealthcare Capital's strategy, a proprietary investment approach called Integrated BioSci Investing was developed blending time-tested value and growth in investing with superior medical, scientific, and business expertise. The strategy highlights the edge of utilizing medical professionals and scientists with business knowledge for biotech stock selection. The fund targets businesses with sufficient market cap to successfully finance a drug's development, from research to commercialization. Smaller-cap companies with a $250 million to $2 billion capitalization are favored opportunities as they are uniquely poised for outsized growth while still enjoying sufficient liquidity unlike in the private markets. Invest in promising biotech opportunities by joining the Evergrowth Fund now! Take advantage of carefully selected investments designed for increased profits. Put your faith into the future's Pioneers! #Investment #Growth #Healthcare #Success

The biotech IPO landscape, as detailed by industry analysts Ben Fidler and Gwendolyn Wu, highlights a decade-long period where biotech firms found Wall Street's doors wide open, driven by scientific breakthroughs and the tangible successes of companies in delivering new treatments. The peak of this trend was observed in 2021, with over 100 biotechs making their market debut, collectively raising nearly $15 billion—a testament to the robust appetite for investment in biotech innovation. However, the transition from 2021 into 2022 marked a significant shift, with a downturn across the sector leading to a dramatic fall in the stock prices of newly public companies. This downturn not only cooled the pace of IPOs but also underscored the volatile nature of the biotech industry's relationship with public markets. In the wake of this shift, only 19 drugmakers managed to price initial share sales last year, illustrating a more challenging landscape for emerging biotechs aiming for public market entry. This evolving scenario raises pertinent questions about the future of biotech IPOs. Which emerging biotechs will navigate the challenging path to the public markets successfully? Which will manage to create value, and which will falter? Furthermore, the types of companies that earn the best returns, their investors, and the strategies that underpin successful transitions from private to public entities are of keen interest to stakeholders across the biotech ecosystem. Edward Narke Enkrisi

During the pandemic the biotech funding environment peaked with IPOs, company valuations, and VC funding reaching new records. Since then, there has been a reversal in public market sentiment for biotechs; however, VC funding for early-stage biotechs has continued to remain robustly above pre-pandemic levels, with over $20Bn raised in 2022 and over $12Bn raised in the first three quarters of 2023. In this recently published article, my colleagues Olivier, Emily, Christian, Anthony, Michelle and former colleague Ahti quantify the VC funding landscape for early stage biotechs over the past 4 years and identify trends in the quantity, size, and thematic focus of those investments.